Replay available

Aktis Oncology, Inc. (AKTS) Q3 2023 Earnings Call

Aktis Oncology, Inc. (NASDAQ: AKTS) Q3 2023 earnings conference call, held 2023-05-08. Replay captured from the company's public earnings webcast.

Mon, May 8, 2023 at 8:00 AMendedReplay
Aktis Oncology, Inc. (AKTS) Q3 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Conference Call Host

Investor Relations Representative

Jeff Scheele

Founder and CEO

Ken Bowler

Chief Financial Officer

Dave Eichle

EVP of Business Development

Anthony Stowes

Analyst at Craig Hallam Capital Group

Suze Bezleva

Analyst at Rook MKM

Robert Aguano

Analyst at Piper Sandler (asking on behalf of Harsh Kumar)

Replay transcript excerpt

And welcome to the Acoustics Technology Festival 2023 third quarter conference call. As a reminder, this conference call is being recorded. At the conclusion of the company's presentation, Acoustics Management will take questions. To ask a question, please press star 1 on your keypad to be placed into the queue. A replay of the call will be available on the investor relations session of the Acoustics website. Thank you, Operator, and good morning to everyone on the call. Welcome to ACUSTA's third quarter fiscal 2023 conference call. We are joined today by our founder and CEO, Jeff Scheele, CFO, Ken Bowler, and EVP of Business Development, Dave Eichle. Before we begin, please note that today's presentation includes forward-looking statements about our business outlook. All statements other than statements of historical facts included in this conference call such as expectations regarding our strategies and operations, including the timing and prospects of product development and customer orders and design wins, possible collaborative or partnering relationships, litigation matters, and expected financial and operating results, are forward-looking statements. Such forward-looking statements are predictions based on the company's expectations as of today and are subject to numerous risks and uncertainties. The company and our management team assume no obligation to update any forward-looking statements made on today's call. Our SEC filings mention important factors that could cause actual results to differ materially. Please refer to our latest Form 10-K and Form 10-Q filed with the SEC to get a better understanding of those risks and uncertainties. In addition, our presentation today will also refer to certain non-GAAP financial measures. A reconciliation of these meas...

More from Aktis Oncology, Inc.